Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who need tracheal intubation for mechanical ventilation and need 6-24 h of sedation after randomization, as anticipated;~2. The target RASS score is between +1 and -2;~3. 18 ≤ age \< 80 years old; with no restriction on gender;~4. 18 kg/m2 ≤ BMI ≤ 30 kg/m2;~5. The patients or their family members well understand the purpose and significance of the trial, voluntarily participate in this clinical trial, and sign the informed consent form.~Exclusion Criteria:~1. Patients known to be allergic to eggs, soy products, opioids and their antidotes, and propofol; patients having contraindications to propofol, opioids and their antidotes;~2. Patients having the following medical history or evidence at screening, which may increase sedation/anesthesia risk:~   1. Cardiovascular system: Class III and IV heart failure by New York Heart Association (NYHA), Adams-Stokes syndrome; acute coronary syndrome (ACS) within 6 months prior to screening; bradycardia requiring medications and/or heart rate ≤ 50 beats/min; serious arrhythmia history such as Degree II-III atrioventricular block (excluding patients with pacemakers); acute and chronic myocarditis; systolic pressure ≤ 90 mmHg even when large dose of vasoactive drug (such as norepinephrine ≥ 0.6 μg/kg/min) is used;~  2. Patients with mental disorders (such as schizophrenia, depression, etc.) and cognitive impairment; past abuse history of psychotropics and anesthetics, and long-term use of psychotropics;~  3. Patients with moderate to severe hepatic and renal dysfunctions (liver function: Child-Pugh Grade B and C, scale in Annex 9; renal function: glomerular filtration rate eGFR ≤ 60 mL/(min•1.73 m2) \[eGFR is calculated with the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 × serum creatinine (SCr)-1.154 × age-0.203 × 0.742 (female)\]; patients under dialysis;~  4. Epileptic seizures, convulsions; craniocerebral injury, intracranial hypertension, cerebral aneurysms; Glasgow Coma Score (GCS) ≤ 12 (scale in Annex 6); SOFA \> 9 (scale in Annex 7);~  5. Expected survival ≤ 72 h;~3. Laboratory measures at screening period meet the following criteria:~   1. Neutrophil count ≤ 1.0 × 10\^9/L;~  2. Platelet count ≤ 50 × 10\^9/L;~  3. Hemoglobin ≤ 70 g/L;~4. Pregnant or lactating females; fertile females or males reluctant to receive contraception through the study; any subject planning for pregnancy within 1 month after the study (including male subject);~5. Participated in other drug clinical trials within 1 month prior to screening; Other reasons rendering a subject unsuitable for participation in this study as per the judgment of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HSK3486 (Type: EXPERIMENTAL): HSK3486 for Sedation
- Propofol (Type: ACTIVE_COMPARATOR): Propofol for Sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).